Johnson & Johnson (JNJ)
- Previous Close
145.74 - Open
146.15 - Bid 145.72 x 1000
- Ask 145.70 x 800
- Day's Range
144.54 - 146.92 - 52 Week Range
143.13 - 175.97 - Volume
2,747,485 - Avg. Volume
7,452,859 - Market Cap (intraday)
353.732B - Beta (5Y Monthly) 0.53
- PE Ratio (TTM)
19.76 - EPS (TTM)
7.43 - Earnings Date Jul 17, 2024
- Forward Dividend & Yield 4.96 (3.40%)
- Ex-Dividend Date May 20, 2024
- 1y Target Est
174.21
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
www.jnj.com131,900
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: JNJ
Related Videos: JNJ
Performance Overview: JNJ
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: JNJ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: JNJ
Valuation Measures
Market Cap
351.20B
Enterprise Value
357.61B
Trailing P/E
19.62
Forward P/E
13.68
PEG Ratio (5yr expected)
0.88
Price/Sales (ttm)
4.48
Price/Book (mrq)
5.11
Enterprise Value/Revenue
4.37
Enterprise Value/EBITDA
15.94
Financial Highlights
Profitability and Income Statement
Profit Margin
47.37%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
85.65B
Net Income Avi to Common (ttm)
19.17B
Diluted EPS (ttm)
7.43
Balance Sheet and Cash Flow
Total Cash (mrq)
22.93B
Total Debt/Equity (mrq)
44.25%
Levered Free Cash Flow (ttm)
--
Research Analysis: JNJ
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: JNJ
Analyst Report: Johnson & Johnson
Johnson & Johnson is a diversified global healthcare company that develops, manufactures and markets products in two business segments: Innovative Medicine (formerly Pharmaceuticals) and MedTech.
RatingBullishPrice TargetMarket Update: DFS, JNJ, LVS, TRV
U.S. stocks were higher on Thursday morning. Initial jobless claims were 212,000 for the latest week, unchanged from the previous-week's revised level. Ongoing unemployment was 1,812,000, virtually unchanged from the previous week. The Dow was up 0.5%, the S&P 500 rose 0.4% and the Nasdaq gained 0.3%. Crude oil is trading above $82 per barrel and gold rose $9 to $2397 per ounce.
Analyst Report: Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
RatingBullishPrice TargetAnalyst Report: Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
RatingBullishPrice Target